2020
Accuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival.
Srivastava A, Patel H, Kim S, Kim I, Singer E, Jang T. Accuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival. Journal Of Clinical Oncology 2020, 38: e17058-e17058. DOI: 10.1200/jco.2020.38.15_suppl.e17058.Peer-Reviewed Original ResearchRetroperitoneal lymph node dissectionNonseminomatous germ cell tumorsPrimary retroperitoneal lymph node dissectionCS I patientsNational Cancer DatabaseI patientsClinical stageOverall survivalClinical stagingTesticular nonseminomatous germ cell tumorsLymph node dissectionQuarter of patientsKaplan-Meier methodNodal disease burdenGerm cell tumorsUpstaging of diseaseCS1 patientsPathologic nodalPN3 diseasePrior chemotherapyNode dissectionIIA patientsMeier methodClinical outcomesTesticular cancer
2019
Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer
Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Seo S, Kang H, Kim W, Lee J, Ryu D, Choi J, Kim I, Moon S, Choi Y, Yun S, Kim W. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer 2019, 17: e704-e711. PMID: 31088707, DOI: 10.1016/j.clgc.2019.04.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorBone Morphogenetic Protein 4Cell-Free Nucleic AcidsDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, Tumor SuppressorGTPase-Activating ProteinsHumansMaleMiddle AgedNuclear ProteinsPrognosisSurvival AnalysisUrinary Bladder NeoplasmsConceptsProgression-free survivalCox regression analysisRecurrence-free survivalDisease recurrenceBladder cancerNon-muscle invasive bladder cancerInvasive bladder cancer patientsWorse progression-free survivalMultivariate Cox regression analysisWorse recurrence-free survivalKaplan-Meier analysisKaplan-Meier curvesBladder cancer patientsRegression analysisUrinary cell-free DNAValuable novel biomarkersCell-free DNANMIBC patientsClinical outcomesCancer patientsDisease progressionPrognostic markerReal-time PCRNovel biomarkersIndependent factors
2018
Correlation of Prostate Cancer CHD1 Status with Response to Androgen Deprivation Therapy: a Pilot Study.
Tabakin A, Sadimin E, Tereshchenko I, Kareddula A, Stein M, Mayer T, Hirshfield K, Kim I, Tischfield J, DiPaola R, Singer E. Correlation of Prostate Cancer CHD1 Status with Response to Androgen Deprivation Therapy: a Pilot Study. 2018, 2 PMID: 30714046, PMCID: PMC6358174.Peer-Reviewed Original ResearchMonths of ADTProstate cancerProstate-specific antigen (PSA) recurrenceSpecific antigen recurrenceAndrogen deprivation therapyAdditional larger studiesProstate cancer patientsLymph node tissueCHD1 deletionDeprivation therapySerum PSAAndrogen deprivationClinical outcomesCancer patientsImmunohistochemical stainsTissue microarrayNode tissueERG fusionLarger studyIndependent correlationTumor suppressor genePilot studyStrong associationPatientsProstatectomy
2013
Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study
Kim I, Modi P, Sadimin E, Ha Y, Kim J, Skarecky D, Cha D, Wambi C, Ou Y, Yuh B, Park S, Llukani E, Albala D, Wilson T, Ahlering T, Badani K, Ahn H, Lee D, May M, Kim W, Lee D. Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study. Journal Of Urology 2013, 190: 527-534. PMID: 23485503, DOI: 10.1016/j.juro.2013.02.073.Peer-Reviewed Original ResearchConceptsProstatic anterior fat padAnterior fat padLymph node metastasisMetastatic diseaseLymph nodesNode metastasisFat padPathological analysisMost patientsConcomitant pelvic lymph node dissectionPelvic lymph node dissectionBiochemical recurrence-free survivalAdjuvant/salvage therapyLymph node dissectionCharacteristics of patientsHigh-risk featuresTertiary care centerRecurrence-free survivalMulti-institutional studyPerioperative characteristicsSalvage therapyAdjuvant therapyNode dissectionAndrogen ablationClinical outcomes
2011
RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer
Yan C, Kim Y, Ha Y, Kim I, Kim Y, Yun S, Moon S, Bae S, Kim W. RUNX3 methylation as a predictor for disease progression in patients with non‐muscle‐invasive bladder cancer. Journal Of Surgical Oncology 2011, 105: 425-430. PMID: 22311819, DOI: 10.1002/jso.22087.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overCarcinoma in SituCarcinoma, Transitional CellChildCore Binding Factor Alpha 3 SubunitDisease ProgressionDNA MethylationDNA, NeoplasmFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPolymerase Chain ReactionPrognosisPromoter Regions, GeneticSurvival RateUrinary Bladder NeoplasmsYoung AdultConceptsDisease progressionRUNX3 methylation statusRUNX3 methylationTumor stageBladder cancerTumor gradeNMIBC progressionInvasive bladder cancer patientsWorse progression-free survivalProgression-free survivalInvasive bladder cancerPoor clinical outcomeKaplan-Meier estimatesBladder cancer patientsMethylation statusNumber of tumorsHypermethylation of RUNX3Methylation-specific polymerase chain reactionNMIBC samplesAdvanced diseaseClinical outcomesClinicopathological characteristicsIndependent predictorsCancer patientsG3 tumors
2001
Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma
Shariat S, Kim J, Andrews B, Kattan M, Wheeler T, Kim I, Lerner S, Slawin K. Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001, 92: 2985-2992. PMID: 11753975, DOI: 10.1002/1097-0142(20011215)92:12<2985::aid-cncr10175>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsMuscle-invasive transitional cell carcinomaTransitional cell carcinomaT1 transitional cell carcinomaPreoperative plasma levelsPlasma TGFDisease recurrenceIndependent predictorsLymph nodesClinical outcomesPlasma levelsBladder carcinomaGrowth factorDisease-specific mortalityDisease-specific survivalRegional lymph nodesSubgroup of patientsStrong independent predictorGrowth factor-β1Intravesical immunoCarcinoma metastaticLymphovascular invasionSpecific survivalRadical cystectomyPathologic featuresCell carcinomaPredictive value of expression of transforming growth factor‐β1 and its receptors in transitional cell carcinoma of the urinary bladder
Kim J, Shariat S, Kim I, Menesses‐Diaz A, Tokunaga H, Wheeler T, Lerner S. Predictive value of expression of transforming growth factor‐β1 and its receptors in transitional cell carcinoma of the urinary bladder. Cancer 2001, 92: 1475-1483. PMID: 11745225, DOI: 10.1002/1097-0142(20010915)92:6<1475::aid-cncr1472>3.0.co;2-x.Peer-Reviewed Original ResearchConceptsTransitional cell carcinomaBladder transitional cell carcinomaInvasive tumor stageOverexpression of TGFDisease progressionIndependent predictorsCell carcinomaTumor stageLoss of expressionTGF betaGrowth factorDisease-specific survivalAltered expressionExpression of TGFGrowth factor-β1Lymphovascular invasionRadical cystectomySpecific survivalClinical outcomesCystectomy specimensUrinary bladderImmunohistochemical stainingBlinded fashionFactor-β1Predictive value